Download PDF

1. Company Snapshot

1.a. Company Description

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide.Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors.The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd.


for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc.to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc.Fate Therapeutics, Inc.


was incorporated in 2007 and is headquartered in San Diego, California.

Show Full description

1.b. Last Insights on FATE

Fate Therapeutics' recent performance was negatively driven by high research and development expenses, which may have outweighed the company's Q4 earnings beat. The biotech firm's quarterly loss of $0.31 per share was narrower than expected, but its high medical care ratios and increasing expenses may have concerned investors. Additionally, the company's recent employee inducement awards, which may be seen as a positive move to attract talent, may have also contributed to the negative sentiment.

1.c. Company Highlights

2. Transcript Summary

Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.

Request Coverage

3. NewsRoom

Card image cap

Fate Therapeutics to Present at Piper Sandler 37th Annual Healthcare Conference

Nov -25

Source: globenewswire.com

Card image cap

Fate Therapeutics, Inc. (NASDAQ:FATE) Given Average Rating of “Hold” by Brokerages

Nov -18

Source: defenseworld.net

Card image cap

Robert Bruce's Strategic Moves: AT&T Inc. Sees a -1.41% Portfolio Impact

Nov -13

Source: gurufocus.com

Card image cap

Fate Therapeutics (FATE) Reports Q3 Loss, Beats Revenue Estimates

Nov -13

Source: zacks.com

Card image cap

Fate Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates

Nov -13

Source: globenewswire.com

Card image cap

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Nov -04

Source: globenewswire.com

Card image cap

3 Cancer-Focused Stocks Showing Strong Pipeline Progress

Oct -28

Source: zacks.com

Card image cap

Fate Therapeutics Presents New Clinical Data at ACR Convergence 2025 Demonstrating Immune Remodeling and Durable Responses in Patients with Systemic Lupus Erythematosus Treated with FT819 Off-the-Shelf CAR T-Cell Therapy

Oct -26

Source: globenewswire.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (12.53%)

6. Segments

Cellular Immunotherapies

Expected Growth: 12.53%

Fate Therapeutics' cellular immunotherapies growth is driven by increasing adoption of cancer treatments, advancements in gene editing technologies, and strategic partnerships. The company's proprietary iPSC product platform and pipeline of off-the-shelf immuno-oncology products also contribute to growth. Additionally, the growing demand for personalized medicine and increasing investments in cell therapy research further support the segment's 12.53% growth.

7. Detailed Products

FT516

FT516 is a natural killer (NK) cell product candidate derived from a clonal master iPSC line, designed to target multiple tumor-associated antigens and to have enhanced anti-tumor activity.

FT596

FT596 is a universal, off-the-shelf NK cell product candidate derived from a clonal master iPSC line, designed to target multiple tumor-associated antigens and to have enhanced anti-tumor activity.

FT819

FT819 is a T-cell receptor (TCR) product candidate derived from a clonal master iPSC line, designed to target the tumor-associated antigen MUC16.

FT538

FT538 is a CAR-T cell product candidate derived from a clonal master iPSC line, designed to target the tumor-associated antigen CD38.

FT576

FT576 is a CAR-T cell product candidate derived from a clonal master iPSC line, designed to target the tumor-associated antigen BCMA.

8. Fate Therapeutics, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Fate Therapeutics, Inc. has a moderate threat of substitutes due to the presence of alternative gene editing technologies such as CRISPR and TALEN. However, the company's proprietary iPSC platform provides a unique value proposition that differentiates it from competitors.

Bargaining Power Of Customers

Fate Therapeutics, Inc. has a low bargaining power of customers due to the lack of direct sales to end-consumers. The company primarily sells its products to pharmaceutical and biotechnology companies, which have limited negotiating power.

Bargaining Power Of Suppliers

Fate Therapeutics, Inc. has a moderate bargaining power of suppliers due to the presence of multiple suppliers of raw materials and services. However, the company's dependence on a few key suppliers for critical components may limit its negotiating power.

Threat Of New Entrants

Fate Therapeutics, Inc. faces a high threat of new entrants due to the growing interest in gene editing and cell therapy. New companies with innovative technologies may enter the market, increasing competition and potentially disrupting the company's market share.

Intensity Of Rivalry

Fate Therapeutics, Inc. operates in a highly competitive industry with multiple players vying for market share. The company faces intense rivalry from established players and new entrants, which may lead to pricing pressure and increased marketing expenses.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 21.94%
Debt Cost 3.95%
Equity Weight 78.06%
Equity Cost 12.95%
WACC 10.97%
Leverage 28.10%

11. Quality Control: Fate Therapeutics, Inc. passed 4 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Eterna Therapeutics

A-Score: 3.3/10

Value: 7.2

Growth: 5.0

Quality: 5.8

Yield: 0.0

Momentum: 1.5

Volatility: 0.3

1-Year Total Return ->

View Full Report
Stock-Card
Chimerix

A-Score: 3.3/10

Value: 6.2

Growth: 3.7

Quality: 5.0

Yield: 0.0

Momentum: 5.0

Volatility: 0.0

1-Year Total Return ->

View Full Report
Stock-Card
Arcus Biosciences

A-Score: 3.2/10

Value: 6.6

Growth: 3.6

Quality: 4.8

Yield: 0.0

Momentum: 1.5

Volatility: 2.7

1-Year Total Return ->

View Full Report
Stock-Card
Fate Therapeutics

A-Score: 2.9/10

Value: 7.8

Growth: 4.0

Quality: 4.3

Yield: 0.0

Momentum: 0.5

Volatility: 0.7

1-Year Total Return ->

View Full Report
Stock-Card
Lexicon Pharmaceuticals

A-Score: 2.8/10

Value: 6.6

Growth: 3.2

Quality: 4.4

Yield: 0.0

Momentum: 2.0

Volatility: 0.3

1-Year Total Return ->

View Full Report
Stock-Card
Palatin Technologies

A-Score: 2.4/10

Value: 8.2

Growth: 0.0

Quality: 6.0

Yield: 0.0

Momentum: 0.0

Volatility: 0.3

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

1.08$

Current Price

1.08$

Potential

-0.00%

Expected Cash-Flows